Details for Patent: 8,252,331
✉ Email this page to a colleague
Which drugs does patent 8,252,331 protect, and when does it expire?
Patent 8,252,331 protects OSMOLEX ER and is included in one NDA.
This patent has eleven patent family members in nine countries.
Summary for Patent: 8,252,331
| Title: | Osmotic device containing amantadine and an osmotic salt |
| Abstract: | The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is modified from a first order release profile to a zero order, pseudo-zero order or sigmoidal release profile by increasing the amount of the osmotic salt in the core of the device. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. |
| Inventor(s): | Meyer; Glenn A. (Wilmington, NC), Feleder; Ethel C. (Buenos Aires, AR), Ricci; Marcelo A. (Buenos Aires, AR), Coppari; Marcelo A. (Buenos Aires, AR), Befumo; Marcelo F. (Buenos Aires, AR), Faour; Joaquina (Buenos Aires, AR), Vergez; Juan A. (Buenos Aires, AR) |
| Assignee: | Osmotica Kereskedelmi es Szolgaltato, KFT (Budapest, HU) |
| Application Number: | 11/287,882 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,252,331 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Device; Dosage form; |
Drugs Protected by US Patent 8,252,331
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-004 | Apr 22, 2020 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Adamas Operations | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,252,331
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 053986 | ⤷ Try a Trial | |||
| Australia | 2005328058 | ⤷ Try a Trial | |||
| Brazil | PI0515761 | ⤷ Try a Trial | |||
| Canada | 2589479 | ⤷ Try a Trial | |||
| European Patent Office | 1834638 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
